Which stent type shows better results for patients with myocardial ischemia in the Chinese trial?
Patients with myocardial ischemia often need stents to keep their coronary arteries open. A specific 2024 trial in China compared a novel iron bioresorbable scaffold against standard metallic everolimus-eluting stents. The study measured how much the artery narrowed over two years to see which device performed better.
What the research says
Results showed that the iron bioresorbable scaffold had higher late lumen loss than the everolimus-eluting stents 1. This means the standard everolimus-eluting stents maintained better blood flow in the artery over the two-year follow-up period 1. The trial was conducted across 36 centers in China and included patients with one or two new lesions 1.
What to ask your doctor
- Does the iron bioresorbable scaffold show better long-term results than everolimus-eluting stents for my specific case?
- What are the risks of higher late lumen loss if I choose a bioresorbable scaffold?
- Are there other stent types available that might prevent artery narrowing better than the iron scaffold?
- How often should I return for follow-up imaging to check my artery after stent placement?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.